0001209191-20-059216.txt : 20201118
0001209191-20-059216.hdr.sgml : 20201118
20201118182504
ACCESSION NUMBER: 0001209191-20-059216
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20201118
FILED AS OF DATE: 20201118
DATE AS OF CHANGE: 20201118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moriarty John B
CENTRAL INDEX KEY: 0001564621
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39712
FILM NUMBER: 201326264
MAIL ADDRESS:
STREET 1: ALEXION PHARMACEUTICALS
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001750284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 300409740
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 512 2ND STREET, 4TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
BUSINESS PHONE: (415) 651-3316
MAIL ADDRESS:
STREET 1: 512 2ND STREET, 4TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-11-18
0
0001750284
Olema Pharmaceuticals, Inc.
OLMA
0001564621
Moriarty John B
C/O OLEMA PHARMACEUTICALS, INC.
512 2ND STREET, 4TH FLOOR
SAN FRANCISCO
CA
94107
0
1
0
0
EVP, Ch. Legal Officer & Sec.
Stock Option (Right to Buy)
4.824
2030-09-18
Common Stock
252060
D
25% of the shares subject to the option vest on September 8, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable.
/s/ John B. Moriarty, Jr.
2020-11-18
EX-24.3_945895
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS that the undersigned hereby constitutes and appoints
each of Shane Kovacs of Olema Pharmaceuticals, Inc. (the "Company"), and Jodie
Bourdet, Kim Merritt and Kris Tsao Cachia of Cooley LLP, signing individually,
as the undersigned's true and lawful attorneys-in-fact and agents to:
1. Prepare, execute for and on behalf of the undersigned, and submit to the
Securities and Exchange Commission (the "SEC"), in the undersigned's name and
capacity as an officer, director and/or beneficial owner more than 10% of a
registered class of securities of the Company, Forms 3, 4 and 5 (including any
amendments thereto and joint filing agreements in connection therewith) in
accordance with Section 16 of the Securities Exchange Act of 1934, as amended,
and the rules thereunder (the "Exchange Act");
2. do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to prepare and execute any such Forms 3, 4 or 5,
prepare and execute any amendment or amendments thereto, and joint filing
agreements in connection therewith, and file such forms with the SEC and any
stock exchange, self-regulatory association or similar authority; and
3. take any other action of any type whatsoever in connection with the foregoing
which, in the opinion of such attorney in-fact, may be of benefit to, in the
best interest of, or legally required of, the undersigned, it being understood
that the documents executed by such attorney in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and
their substitutes, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
earliest to occur of (a) the undersigned is no longer required to file Forms 3,
4 and 5 with respect to the undersigned's holdings of and transactions in
securities issued by the Company, (b) revocation by the undersigned in a signed
writing delivered to the Company and the foregoing attorneys-in-fact or (c) as
to any attorney-in-fact individually, until such attorney-in-fact is no longer
employed by the Company or employed by or a partner at Cooley LLP, or another
law firm representing the Company, as applicable.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 25th day of October, 2020.
/s/ John B. Moriarty
JOHN B. MORIARTY, JR., J.D.